Edition:
United States

Hansa Medical AB (HMED.ST)

HMED.ST on Stockholm Stock Exchange

276.20SEK
7:07am EST
Change (% chg)

0.40kr (+0.15%)
Prev Close
275.80kr
Open
275.00kr
Day's High
278.00kr
Day's Low
267.80kr
Volume
103,420
Avg. Vol
196,133
52-wk High
349.40kr
52-wk Low
196.80kr

Summary

Name Age Since Current Position

Ulf Wiinberg

59 2018 Independent Chairman of the Board

Soeren Tulstrup

53 2018 President, Chief Executive Officer

Eva-Maria Joed

49 2015 Chief Financial Officer, Vice President

Christian Kjellman

51 Senior Vice President, Research and Development

Karin Aschan

57 2016 Vice President, Regulatory Affairs

Henk Doude van Troostwijk

53 2016 Vice President, Commercial Operations

Vincenza Nigro

2018 Vice President, Global Medical Affairs

Max Sakajja

37 2017 Vice President, Corporate Strategy

Lena Winstedt

49 Vice President, Project Management

Emanuel Bjorne

45 Vice President, Business Development and Investor Relations

Angelica Loskog

45 2016 Director

Andreas Eggert

51 2018 Independent Director

Anders Gersel Pedersen

66 2018 Independent Director

Stina Gestrelius

69 2007 Independent Director

Birgit Stattin Norinder

70 2018 Independent Director

Biographies

Name Description

Ulf Wiinberg

Mr. Ulf Wiinberg has been Independent Chairman of the Board of Directors at Hansa Medical AB since March 20, 2018. He was Acting Chief Executive Officer of the Company from November 8, 2017 till March 20, 2018. He has previously been Independent Chairman of the Board of Directors of Hansa Medical AB since May 11, 2016. He is an experienced healthcare industry professional who has served the boards of several healthcare industry associations. At Wyeth, he has been both President of the global consumer health care business and President for the European pharma business, and he has also held the position as CEO of H Lundbeck A/S, a pharmaceutical company specialized in psychiatric and neurological disorders, for several years. Ulf is a non-executive Board member at Alfa Laval AB, Agenus Inc and UCB. He is also Chairman of Sigrid Therapeutics AB. He also serves as CEO and Chairman of Ulf Wiinberg consulting&invest AB.

Soeren Tulstrup

Mr. Soeren Tulstrup has been President and Chief Executive Officer of Hansa Medical AB since March 20, 2018. He has a broad and extensive background as senior executive in the global biopharma industry. Recently, he served as CEO of Vifor Pharma AG (VTX:VIFN), a Glattbrugg, Switzerland-based global pharmaceutical company with a market-leading position within chronic kidney disease, annual sales of approximately USD 1 billion and 2,000 employees. Prior to joining Vifor Pharma, he served as Senior Vice President, Global Franchise Head, MPS at Shire Pharmaceuticals, securing strong market performance of Elaprase (INN: Idursulfase), an enzyme-based treatment of the rare disease Hunter syndrome. He has also served as CEO of Santaris Pharma A/S, now part of Roche, a leading clinical stage biopharmaceutical company developing RNA -targeted drugs for various therapeutic areas including cancer and rare genetic diseases. Furthermore, he has served in several senior commercial roles within Merck & Co., Inc. and Sandoz Pharma AG (Novartis) and he holds a Master of Science, Economics and Business Administration from Copenhagen Business School.

Eva-Maria Joed

Ms. Eva-Maria Joed has served as Vice President and Chief Financial Officer of Hansa Medical AB since 2015. Eva-Maria joined Hansa Medical in 2015 and has long and wide experience within finance. She has held positions both as Chief Accountant and CFO and worked in international companies such as Kemira Kemi AB, Johns Manville AB within the Berkshire Hathaway group and Procordia Food AB. She has also been responsible for implementing new financial systems and policies, and for IT. Eva-Maria holds Master of Science in Business and Economics from Lund University.

Christian Kjellman

Dr. Christian Kjellman, Ph.D. serves as Senior Vice President, Research and Development at Hansa Medical AB. He has previously served as Chief Scientific Officer at the Company since 2008. He was previously Senior Scientist at BioInvent AB. Prior to that, he was Head of Research at Cartela AB, mainly focusing on novel drug target evaluation. He has experience as Researcher in Cell and Molecular Biology and as Assistant Professor in Molecular Genetics at Lunds Universitet (Lund University). He holds Master of Science degree in Chemical Biology and Doctorate in Philosophy degree in Tumor Immunology, both from Lunds Universitet.

Karin Aschan

Ms. Karin Aschan has been Vice President, Regulatory Affairs at Hansa Medical AB since the third quarter of 2016. She has a long experience from working within Regulatory Affairs, initially at Astra Zeneca, and has worked on EU and US projects in all phases through the first clinical study up to marketing phase. Karin has held the position as Head of Regulatory Affairs at Active Biotech and at Clinical Data Care. She has also been working as an independent regulatory consultant. Karin holds M.Sc. in Pharmacy from Uppsala University.

Henk Doude van Troostwijk

Mr. Henk J. Doude van Troostwijk has served as Vice President, Commercial Operations at Hansa Medical AB since May 12, 2016. He has management experience in sales and marketing from the areas of transplantation and orphan drugs. Before joining Hansa Medical in 2016, Henk served as General Manager of European Commercial Operations and Emerging Markets at Raptor Pharmaceuticals, an orphan disease focused global biopharma company based in the US. Prior to that, he held the position of Business Unit Director Oncology and Transplantation at Genzyme Europe BV. Henk holds an MBA from Henley Management College at the University of Reading, UK.

Vincenza Nigro

Ms. Vincenza Nigro has been Vice President, Global Medical Affairs at Hansa Medical AB since September 17, 2018. Most recently, Ms. Nigro built and led the global medical affairs function at Veloxis, a specialty pharmaceutical company focused on transplantation. Previously, she spent over a decade at Hoffmann-La Roche in the US in drug discovery, clinical development and commercial roles within immunology and transplantation. She has also held a commercial leadership role at US specialty pharma company Enzon Pharmaceuticals, which was focused on oncology. Ms. Nigro holds a Bachelor of Science degree in Biology from Fairleigh Dickinson University and an MBA degree from Massachusetts Institute of Technology (MIT).

Max Sakajja

Mr. Max Sakajja has been Vice President, Corporate Strategy at Hansa Medical AB since 2017. He has broad corporate development background and had previously worked with corporate finance at Biovitrum/SOBI in the position of Director Mergers & Acquisitions. Before joining Hansa Medical, Max worked with strategy and business development at Envirotainer as the Global Product and Service Development Manager. Max holds a M.Sc. in Biotechnology from the Royal Institute of Technology.

Lena Winstedt

Dr. Lena Winstedt serves as Vice President, Project Management at Hansa Medical AB. She has previously been Clinical Research Director at the Company. She has experience in the clinical development of biopharmaceuticals and small molecules. Prior to joining the Company in 2011, she served as Clinical Project Manager at BioInvent International AB focused on Phase I clinical trials for biopharmaceuticals in Europe and the United States. Prior to that, she was International Clinical Project Manager at Genmab A/S and Clinical Research Associate at H. Lundbeck AB. She holds Master of Science degree in Molecular Biology from both Lunds Universitet (Lund University) and the University of Glasgow, and Doctorate in Philosophy degree in Microbiology from Lund University.

Emanuel Bjorne

Mr. Emanuel Bjorne serves as Vice President, Business Development and Investor Relations at Hansa Medical AB. He was Corporate Development Director at the Company from November 25, 2014. He was Chief Executive Officer (CEO) of Hansa Medical AB from 2007 until November 25, 2014. He was previously Scientific Project Manager focused on Business Intelligence and Analysis within Pharmaceuticals, Diagnostics and Analytical Instrumentation at Biolin Scientific. Prior to that, he was Analytical Development Chemist at PolyPeptide Labs, focusing on the development of analytical methods based on Mass Spectrometry and Chromatography for peptide drugs in early clinical stage. Previously, he was Member of the Board at Cartela i Malmo AB, and he was Deputy Member of the Board of Directors and CEO of Hansa Medical Utvecklings AB. He holds Master of Science degree in Engineering Physics, focusing on Biophysical Chemistry from both Lunds Universitet (Lund University) and the University of California in Santa Barbara, the United States.

Angelica Loskog

Dr. Angelica Loskog has been Member of the Board of Directors of Hansa Medical AB since May 11, 2016. She is Doctor of Philosophy (Faculty of Medicine) and adjunct professor at the Department of Immunology, Genetics and Pathology at Uppsala University. She is scientific advisor to Nexttobe, CEO of Lokon Pharma AB, as well as chairman of Vivolux AB and Repos Pharma AB and board member of Biomics AB. She is Member of the Company’s Scientific Committee.

Andreas Eggert

Mr. Andreas Eggert has been Independent Director of Hansa Medical AB since May 29, 2018. Andreas has more than 20 years of cross-functional leadership experience including commercial operations, launch and portfolio management, brand strategy, market access, and strategic consulting. He served as Senior Group Vice President, Global Product Strategy & Portfolio Development, and Member of the Corporate Management Committee at H. Lundbeck A/S in Denmark, where he was responsible for multiple new product launches and the commercial leadership for shaping the product portfolio and development pipeline. Previously, Andreas served as Vice President & Global Business Manager at Wyeth/Pfizer in the US. He held several senior commercial positions for Wyeth in the US, Japan and in Germany. Andreas also was a Management Consultant at A.T. Kearney. He holds an MBA from Azusa Pacific University.

Anders Gersel Pedersen

Dr. Anders Gersel Pedersen, M.D., Ph.D. has been Independent Director of Hansa Medical AB since May 29, 2018. Anders has a long experience from the international pharmaceutical industry. Following his degree in medicine and research fellow positions at Copenhagen hospitals, he worked for Eli Lilly for 11 years. In January 2000 he joined H. Lundbeck A/S in Denmark and is currently Executive Vice President of the Research & Development organization, hence responsible for the discovery and development of the product pipeline from pre-clinical activities to post-launch marketing studies. He is a member of Danish Society of Internal Medicine and serves on the supervisory boards of ALK-Abello A/S, Bavarian Nordic A/S, and Genmab A/S. Anders received his medical degree and a doctoral degree in neuro-oncology from the University of Copenhagen and a B.Sc. in Business Administration from Copenhagen Business School.

Stina Gestrelius

Dr. Stina Gestrelius has served as Independent Member of the Board of Directors at Hansa Medical AB since August 2007. She is Member of the Company’s Scientific Committee. She has 40 years of experience in the Pharmaceutical and Biotechnology industries. She is Entrepreneur. She previously served as Head of Research at Biora AB and as Deputy Chief Executive Officer (CEO) of Medicon Valley Alliance. She is currently working with evaluation of research and innovation project proposals via the consultancy company SigridScience and has held several board positions of Scandinavian biotechnology companies including BioActive Polymers AB, Bioara AB, Biogaia AB (publ), Clavis Pharma ASA (publ) and Lipopeptide AB. She holds Master of Science degree in Chemical Engineering and Doctorate of Philosophy degree in Applied Biochemistry, both from Lunds Universitet (Lund University), as well as a honoris causa Doctorate degree from Malmo hogskola.

Birgit Stattin Norinder

Ms. Birgit Stattin Norinder has served as Independent Member of the Board of Directors at Hansa Medical AB since March 20, 2018. She was Chairman of the Board from November 9, 2017 till March 20, 2018. She has previously been Independent Member of the Board of Directors of Hansa Medical AB from May 11, 2016 till November 8, 2017. She was previously Independent Chairman of the Board of Directors at the Company from September 2014 until May 11, 2016. She has been Member of the Company's Board since May 14, 2012. She is Member of the Remuneration Committee and Member of the Audit Committee as well as Chairman of the Scientific Committee of the Company. She has experience from international pharmaceutical and biotechnology companies in Sweden, the United States and the United Kingdom (UK). She has managed several research and development departments. She has also served as Chief Executive Officer and Chairman at Prolifix Ltd., Senior Vice President of Worldwide Product Development at Pharmacia & Upjohn and Dir. Int. Reg. Affairs Division at Glaxo Group Research Ltd. She has also held several Board and Chairman positions at UK, Swedish and Norwegian biotechnology companies. She is Member of the Boards of AddLife AB, Nicox S.A. and Jettesta AB. She was Chairman of the Board of Directors of Wingfirm Pharma AB, Partners for Utvecklingsinvesteringar inom Life Sciences, P.U.L.S. AB and Index Pharmaceutical AB, as well as Board Member of Karo Bio Aktiebolag and Antisoma Plc. She holds a Master of Science degree in Pharmacy from Uppsala Universitet (Uppsala University).